Last reviewed · How we verify
Spironolactone or hydrochlorothiazide
This is a combination of two diuretics: spironolactone (a potassium-sparing aldosterone antagonist) and hydrochlorothiazide (a thiazide diuretic that promotes sodium and water excretion).
This is a combination of two diuretics: spironolactone (a potassium-sparing aldosterone antagonist) and hydrochlorothiazide (a thiazide diuretic that promotes sodium and water excretion). Used for Hypertension, Heart failure with reduced ejection fraction, Edema associated with liver cirrhosis or renal disease.
At a glance
| Generic name | Spironolactone or hydrochlorothiazide |
|---|---|
| Also known as | Aldactone, HCTZ, Thiazide |
| Sponsor | Chiang Mai University |
| Drug class | Combination diuretic (potassium-sparing aldosterone antagonist + thiazide diuretic) |
| Target | Aldosterone receptor (mineralocorticoid receptor) and sodium-chloride cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Spironolactone blocks aldosterone receptors in the collecting duct, reducing sodium reabsorption and potassium excretion, while hydrochlorothiazide inhibits the sodium-chloride cotransporter in the distal convoluted tubule to increase urinary sodium and water loss. Together, they provide complementary diuretic and antihypertensive effects with spironolactone offsetting the potassium-wasting effects of the thiazide.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Edema associated with liver cirrhosis or renal disease
Common side effects
- Hyperkalemia
- Hyponatremia
- Gynecomastia (spironolactone)
- Hyperglycemia
- Hyperuricemia
- Dizziness
Key clinical trials
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study (PHASE3)
- Recurrent Stroke Prevention Clinical Outcome Study (PHASE4)
- Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spironolactone or hydrochlorothiazide CI brief — competitive landscape report
- Spironolactone or hydrochlorothiazide updates RSS · CI watch RSS
- Chiang Mai University portfolio CI